AVEO Oncology Announces Strategic Restructuring

Loading...
Loading...
AVEO Oncology
AVEO
today announced a strategic restructuring designed to optimize resources and reduce expenses to ensure AVEO is well positioned for a successful launch of tivozanib in renal cell carcinoma (RCC) and continued development in other cancer types, while maintaining a focused research engine. In addition, AVEO reported consolidated financial results for the third quarter of 2012, updated its financial guidance and summarized recent developments. “AVEO's primary focus is on the approval and successful commercialization of tivozanib, which will drive the near term future of the company and will be our greatest opportunity for value creation,” said Tuan Ha-Ngoc, president and chief executive officer of AVEO. “AVEO's drug discovery, translational research and Human
See full press release
Posted In: NewsGuidanceManagement
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...